Please login to the form below

Biocon

This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Amgen launched its Kamjinti there in July, with Biocon and Mylan reaching the market with their Ogivri biosimilar in December, and others are in the latter stages of regulatory review.

Latest news

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan and Biocon have launched their biosimilar Herceptin (trastuzumab) under the brand name Ogivri, after Roche tried and failed to get an injunction on sales of biosimilars in the US. . ... Mylan/Biocon’s Herceptin biosimilar is the second to
Amgen CEO says Aimovig is “one of most successful launches”

of weakness from biosimilar competition after Mylan/Biocon launched their Fulphila rival in July.
Roche eyes September FDA verdict for triple NSCLC therapy

Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars. Already a big player in the emerging biosimilars market, Novartis has struck a deal with India’s Biocon in a bid to ... globally”. The deal with Novartis' subsidiary Sandoz
Mylan gets first biosimilar Herceptin OK from FDA

The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... Mylan said in a statement Ogivri is the

More from news
Approximately 10 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...